Sanofi (SNY) Operating Expenses (2009 - 2026)
Sanofi (SNY) posted Operating Expenses of -$5.5 billion for Q2 2026, down 14.49% sequentially from -$4.8 billion in Q1 2026, and down 15.05% YoY from -$6.4 billion in Q2 2025.
Sanofi (SNY) Operating Expenses (2009 - 2026) Analysis & Trends
Sanofi has reported Operating Expenses for 18 years, with the latest figure at -$5.5 billion in Q2 2026.
- Quarterly Operating Expenses fell 15.05% year-over-year to -$5.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$44.9 billion (down 44.24% YoY) and the FY2025 annual result came in at $21.6 billion, up 12.27% from the prior year.
- Operating Expenses eased to -$5.5 billion in Q2 2026 per SNY's latest filing, from -$4.8 billion in the prior quarter.
- Over five years, Operating Expenses peaked at -$4.1 billion in Q1 2024 and troughed at -$20.2 billion in Q4 2025.
- A 5-year average of -$8.0 billion and a median of -$4.6 billion in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses rose 9.29% in 2024, then plunged 225.84% in 2025.
- Over 5 years, Operating Expenses stood at -$15.7 billion in 2022, then declined by 5.9% to -$16.6 billion in 2023, then fell by 6.63% to -$17.7 billion in 2024, then decreased by 14.24% to -$20.2 billion in 2025, then jumped by 73.02% to -$5.5 billion in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered -$5.5 billion, -$4.8 billion, and -$20.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -5.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.46 Bn |
| Mar 31, 2026 | -4.77 Bn |
| Dec 31, 2025 | -20.24 Bn |
| Sep 30, 2025 | -14.44 Bn |
| Jun 30, 2025 | -4.75 Bn |
| Mar 31, 2025 | -4.24 Bn |
| Dec 31, 2024 | -17.71 Bn |
| Sep 30, 2024 | -4.43 Bn |
| Jun 30, 2024 | -4.15 Bn |
| Mar 31, 2024 | -4.11 Bn |
| Dec 31, 2023 | -16.61 Bn |
| Sep 30, 2023 | -4.62 Bn |
| Jun 30, 2023 | -4.58 Bn |
| Mar 31, 2023 | -4.48 Bn |
| Dec 31, 2022 | -15.69 Bn |
| Sep 30, 2022 | -4.42 Bn |
| Jun 30, 2022 | -4.52 Bn |
| Mar 31, 2022 | -4.34 Bn |
| Dec 31, 2021 | -12.47 Bn |
| Sep 30, 2021 | -4.38 Bn |